<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944461</url>
  </required_header>
  <id_info>
    <org_study_id>ACZ1601</org_study_id>
    <nct_id>NCT02944461</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris</brief_title>
  <official_title>Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if Dapsone (Aczone) 7.5% gel is a safe and effective treatment for acne on the
      trunk
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label pilot study to determine the safety and efficacy of Dapsone (Aczone)
      7.5% gel applied daily to the trunk for acne. Subjects will apply Dapsone for 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">September 11, 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects Who Achieve at Least a Two Grade Improvement and a Rating of Clear or Almost Clear on the Investigator Global Assessment (IGA) Scale</measure>
    <time_frame>16 weeks</time_frame>
    <description>Investigator will evaluate global acne severity using the IGA scale as follows: 1= Clear Skin, 2 = Almost Clear, 3 = Mild Severity, 4 = Severe, 5 = Very Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percent Change in Inflammatory Lesion Count at Week 16 Compared to Baseline</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent Change in Non-inflammatory Lesion Count at Week 16 Compared to Baseline</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent Change in Total Lesion Count at Week 16 Compared to Baseline</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Dapsone gel 7.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone 7.5 % gel</intervention_name>
    <description>Dapsone gel 7.5% applied once daily to truncal acne</description>
    <arm_group_label>Dapsone gel 7.5%</arm_group_label>
    <other_name>Aczone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects of any race and at least 12 years of age.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test at
             Baseline and practice a reliable method of contraception throughout the study.

          -  Truncal acne IGA score of 3.

          -  Able to understand the requirements of study and sign Informed Consent/HIPAA forms.

        Exclusion Criteria:

          -  Female subjects who are pregnant , breast feeding or are of childbearing potential who
             are not willing to use a reliable method birth control.

          -  Subjects who have an allergy or sensitivity to any component of the test medication.

          -  Subjects who have not complied with the proper wash out periods for prohibited
             medications.

          -  Evidence of recent drug or alcohol abuse.

          -  Skin disease /disorder that might interfere with the diagnosis or evaluation of
             truncal acne.

          -  Exposure to an investigational drug within 30 days of the Baseline visit.

          -  Medical condition that contraindicates the subject's participation in the study.

          -  History of poor cooperation, non-compliance with medical treatment or unreliability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H. Kircik, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>DermResearch PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Q. DelRosso DO, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <results_first_submitted>February 7, 2019</results_first_submitted>
  <results_first_submitted_qc>February 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02944461/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapsone Gel 7.5%</title>
          <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapsone Gel 7.5%</title>
          <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects Who Achieve at Least a Two Grade Improvement and a Rating of Clear or Almost Clear on the Investigator Global Assessment (IGA) Scale</title>
        <description>Investigator will evaluate global acne severity using the IGA scale as follows: 1= Clear Skin, 2 = Almost Clear, 3 = Mild Severity, 4 = Severe, 5 = Very Severe</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 7.5%</title>
            <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Who Achieve at Least a Two Grade Improvement and a Rating of Clear or Almost Clear on the Investigator Global Assessment (IGA) Scale</title>
          <description>Investigator will evaluate global acne severity using the IGA scale as follows: 1= Clear Skin, 2 = Almost Clear, 3 = Mild Severity, 4 = Severe, 5 = Very Severe</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change in Inflammatory Lesion Count at Week 16 Compared to Baseline</title>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 7.5%</title>
            <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change in Inflammatory Lesion Count at Week 16 Compared to Baseline</title>
          <units>percent change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change in Non-inflammatory Lesion Count at Week 16 Compared to Baseline</title>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 7.5%</title>
            <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change in Non-inflammatory Lesion Count at Week 16 Compared to Baseline</title>
          <units>percent change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change in Total Lesion Count at Week 16 Compared to Baseline</title>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 7.5%</title>
            <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change in Total Lesion Count at Week 16 Compared to Baseline</title>
          <units>percent change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dapsone Gel 7.5%</title>
          <description>Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
Dapsone 7.5 % gel: Dapsone gel 7.5% applied once daily to truncal acne</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>stye, right eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>infected abrasions of legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sunburn arms/chest/back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>gum graft surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M. McAllister</name_or_title>
      <organization>Skin Sciences, PLLC</organization>
      <phone>5024519000</phone>
      <email>mmdermresearch@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

